Related Experiment Video
Updated: Jun 16, 2026

Visualization of DNA Repair Proteins Interaction by Immunofluorescence
Published on: June 26, 2020
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent
Samuel McNeely1, Chiara Conti, Tahir Sheikh
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract:
Checkpoint kinase 1 (Chk1) regulates cell cycle checkpoints and DNA damage repair in response to genotoxic stress. Inhibition of Chk1 is an emerging strategy for potentiating the cytotoxicity of chemotherapeutic drugs. Here, we demonstrate that AZD7762, an ATP -competitive Chk1/2 inhibitor induces gammaH2AX in gemcitabine-treated cells by altering both dynamics and stability of replication forks, allowing the firing of suppressed replication origins as measured by DNA fiber combing and causing a dramatic increase in DNA breaks as measured by comet assay. Furthermore, we identify ATM and DNA-PK, rather than ATR, as the kinases mediating gammaH2AX induction, suggesting AZD7762 converts stalled forks into double strand breaks (DSBs). Consistent with DSB formation upon fork collapse, cells deficient in DSB repair by lack of BRCA2, XRCC3 or DNA-PK were selectively more sensitive to combined AZD7762 and gemcitabine. Checkpoint abrogation by AZD7762 also caused premature mitosis in gemcitabine-treated cells arrested in G(1)/early S-phase. Prevention of premature mitotic entry via Cdk1 siRNA knockdown suppressed apoptosis. These results demonstrate that chemosensitization of gemcitabine by Chk1 inhibition results from at least three cellular events, namely, activation of origin firing, destabilization of stalled replication forks and entry of cells with damaged DNA into lethal mitosis. Additionally, the current study indicates that the combination of Chk1 inhibitor and gemcitabine may be particularly effective in targeting tumors with specific DNA repair defects.
Insights
Inhibiting Checkpoint kinase 1 (Chk1) with AZD7762 enhances gemcitabine chemotherapy by destabilizing replication forks and causing DNA breaks. This combination therapy may be effective against tumors with DNA repair defects.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Checkpoint kinase 1 (Chk1) is crucial for cell cycle checkpoints and DNA repair following genotoxic stress.
- Inhibiting Chk1 is a promising strategy to enhance chemotherapy efficacy.
- AZD7762 is an ATP-competitive inhibitor targeting Chk1/2 kinases.
Purpose of the Study:
- To investigate the mechanisms by which AZD7762 potentiates gemcitabine cytotoxicity.
- To identify the specific DNA damage response pathways involved in AZD7762 and gemcitabine combination therapy.
- To explore the potential of this combination therapy in specific cancer types.
Main Methods:
- Treatment of cells with AZD7762 and gemcitabine.
- Analysis of replication fork dynamics and stability using DNA fiber combing.
- Measurement of DNA breaks via comet assay.
- Assessment of kinase involvement (ATM, DNA-PK, ATR) in gammaH2AX induction.
- Evaluation of sensitivity in cells deficient in DNA double-strand break (DSB) repair.
- Monitoring cell cycle progression and mitotic entry.
- Investigation of apoptosis induction and prevention.
Main Results:
- AZD7762 induces gammaH2AX in gemcitabine-treated cells by altering replication fork dynamics and stability.
- ATM and DNA-PK, not ATR, mediate gammaH2AX induction, suggesting conversion of stalled forks to DSBs.
- Cells deficient in DSB repair (BRCA2, XRCC3, DNA-PK) show increased sensitivity to the combination therapy.
- AZD7762 causes premature mitosis in gemcitabine-treated cells, leading to apoptosis.
- Combination therapy involves origin firing activation, replication fork destabilization, and entry into lethal mitosis.
Conclusions:
- Chemosensitization by Chk1 inhibition involves multiple cellular events: origin firing, replication fork collapse, and premature mitotic entry.
- The combination of AZD7762 and gemcitabine may be particularly effective in tumors with defects in DNA repair pathways.
- Targeting Chk1 offers a viable strategy to overcome gemcitabine resistance and enhance anti-cancer effects.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Restarting Stalled Replication Forks
Homologous Recombination
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of replication.
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of replication.

